Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Loving the bargain sale!
Cheers!
Saw this story for 2-nights in row on the CBS Nightly News. No joke, President Obama should propose an executive order to fast track abuse deterrent drugs through the FDA for commercial distribution. All of these BIG PHARMAS are profiting huge at the expense of patients.
Cheers!
Hmm, if 600,000 shares were sold, 600,000 shares were bought.
Cheers!
Lol, we should be at 2-cents since we did not receive new updates on the NDA filing, and there is no plurb about Elite's abuse deterrent technology in professional medical journal.
Cheers!
Based in the income statement, we see an upward trend in the quarterly reports.
Cheers!
Hakim emphasized that Elite's uplisting to the NASDAQ/AMEX depends on strong fundamentals. Although some shareholders might disagree on his handling on its strategic initiatives, he is staying the course to build strong fundamentals to win the hearts-and-minds of long-term, value investors. We see proof in today's trading volume that more investors are accumulating from day traders, who would need to buy at the higher share prices.
Cheers!
Yes, Elite is worth fighting for if she has value.
Cheers!
As INVESTORS, we do not need to go overboard with professional medical publications for comparative analysis between Elite's technology and that of its competitors. Trial runs and FDA-approvals would do. This is the very reason why academics obsession of being right prevents them from being successful investors because they tend to have paralysis by analysis. For instance, Sir Isaac Newton was a genius that lost in his South Sea investment.
Cheers!
This would ensure another record-breaking revenues in future quarterly reports. A cash flow company that would re-invest the gains towards R & D. Smart play by management, indeed!
Cheers!
Are you implying that KMAG still has a pulse? Dead stocks do not attract investors.
Cheers!
For long-term, value investors, the "sky is the limit." For traders, the "limit is the sky."
Guess we could all agree on the fact that change has been constant for Elite.
Cheers!
Elite's ELI-200 will appear in medical journals once FDA-approval is achieved. We will be in the spot light. Shareholders will have the last laugh, indeed.
Cheers!
Looks like to Aqua that the battle has already been won by Elite before it is ever fought. Elite winning federal mandate would definitely raise the eye brows of BIG PHARMA with billions of dollars in stake.
Cheers!
Elite's phase III trials successfully tested the efficacy of its ELI-200 formulation. Purdue was avoiding a meeting with the FDA.
Cheers!
ELI-200 to the rescue. Elite's formulation is second to none.
https://www.centerwatch.com/clinical-trials/results/new-therapies/nmt-details.aspx?CatID=565
Cheers!
Give me a break, the public knows that Purdue's ADT is inferior to Elite's.
http://www.fiercebiotech.com/story/purdue-pulls-out-fda-panel-abuse-deterrent-oxycontin-just-days-meeting/2015-07-01
Cheers!
No worries, the higher we go, the louder the complaints. Just folks kicking themselves over their indecisiveness when the times are too good of an opportunity to accumulate more shares.
Cheers!
Been saying, "Cheers!", since I first bought ELTP shares at 4-cents under "Old Man" Treppel.
Cheers!
Looking forward to detonating a "Cheers!" bomb when we receive the announcement confirming an NDA filing for ELI-200.
Cheers!
Remind Aqua to complain on the share price when we trend upward with a few ticks. Consolation is not an exact share price, but a range of share prices.
Cheers!
Oh, please. It's an exciting time to be invested in ELTP. Exercising a day-trading mentality would blind your perception of Elite as an undervalued investment and not realize it's fundamentals are of greater significance.
Cheers!
Hopefully, another executive order by President Obama to give the official mandate requiring physicians and hospitals to procure and to prescribe ELI drugs to patients. But this only a long shot.
Cheers!
You cannot have the best ADT/ART if your company is facing lawsuits.
Looks like the battle is already won before it is fought for Elite when compared to Purdue.
Cheers!
The real experts (aka consumers) brought lawsuits against Purdue's pain medication drugs that are the enablers of this drug epidemic.
Cheers!
Pinch my butt, there is only one expert when Elite's ELI products are FDA-approved: the consumer. We all know the customer is always right.
Cheers!
They have a public relations fiasco and lost of trust by the public. Fortunately, Elite is starting with a clean slate. Never underestimate the value of winning the hearts-and-minds of all stakeholders.
Cheers!
Lol, facts are facts. Whose to argue against the evidence? Purdue is undeniably guilty of the atrocities to consumers.
Cheers!
To greedy, CEOs and executives, making huge profits only matters at the expense of subordinate employees and consumers. However, Elite has a corporate policy that values all of its stakeholders and prides itself in developing drugs the right way without cutting corners.
Cheers!
Oxycontin-related lawsuits
S o u r c e
Purdue was involved in measures against prescription drug abuse, particularly of Oxycontin. In 2001, Connecticut Attorney General Richard Blumenthal issued a statement urging Purdue to take action regarding abuse of Oxycontin; he did note that, while Purdue seemed sincere, there was little action being taken beyond "cosmetic and symbolic steps."[7] After Purdue announced plans to reformulate the drug, Blumenthal noted that this would take time, and that "Purdue Pharma has a moral, if not legal, obligation to take effective steps now that address addiction and abuse even as it works to reformulate the drug."[8] The company has since implemented a comprehensive program designed to assist in detection of the illegal trafficking and abuse of prescription drugs without compromising patient access to proper pain control.[citation needed]
In May 2007 the company pleaded guilty to misleading the public about Oxycontin's risk of addiction, and agreed to pay $600 million in one of the largest pharmaceutical settlements in U.S. history. Its president, top lawyer, and former chief medical officer pleaded guilty as individuals to misbranding charges, a criminal violation, and agreed to pay a total of $34.5 million in fines.[9][10] Those executives are: Michael Friedman, the company’s president, who agreed to pay $19 million in fines; Howard R. Udell, its top lawyer, who agreed to pay $8 million; and Dr. Paul D. Goldenheim, its former medical director, who agreed to pay $7.5 million.
In addition three top executives were charged with a felony and sentenced to 400 hours of community service in drug treatment programs.[11]
On October 4, 2007 Kentucky officials sued Purdue because of widespread Oxycontin abuse in Appalachia. A lawsuit filed by Kentucky then-Attorney General Greg Stumbo and Pike County officials demanded millions in compensation.[12]
Kentucky is filing a total of 12 claims against the company, including false advertising, Medicaid fraud, unjust enrichment, and punitive damages. In total the suit could cost Purdue Pharma $1 billion (which is just one-third of its annual revenues from OxyContin).[13]
Cheers!
Sure exposes Purdue's weaknesses and puts the superiority of Elite's abuse-deterrent technology in the forefront.
Cheers!
Putting profits over human lives underlies the intent of its management as purely criminal. This is why Aqua is invested in Elite's technology because addicts lives matters, too.
Cheers!
ELTP has been my best investment, thus far. No need for folks to over/underestimate the value of the company and the competence of management. From a realistic perspective, Elite has delivered on a consistent basis without doubt.
Cheers!
Aqua will sell when she can retire comfortably.
Cheers!
The question is: will ELTP reach $5 without a reverse split? I sure would like to play the options.
Cheers!
We have yet to see the full arsenal of Elite's ELI product line unleashed to the public's consumption of ADT/ART opioids. We all know the lives of those that are addicted to prescription pain medication matters, too.
Cheers!
One thing that is constant about th stock and OTC markets in general is that history repeats itself. ELTP repeating its surge to 97-cents will be no fluke of the imagination as its fundamentals and potential of its ELI product pipeline is realized. When that time comes, a 97-cents or higher PPS could be justified by the markets.
Cheers!
However, this a big win for investors if given 30% of doctors. Elite only needs a slice of the pie.
Cheers!
It takes only 30% to win the hearts-and-minds of doctors. The rest would fall by attrition.
Cheers!
Building a strong consensus of physicians and pharmaceutical experts promotes the case for Elite to pursue ELI-200 and its proprietary technology as the choice for abuse deterrent drugs.
Cheers!
You know that once we receive the NDA filing announcement and successfully achieve FDA-approval for ELI-200, then all LIVES that are addicted to prescribed pain medication WOULD MATTER.
Cheers!